Home › Compare › GREZF vs ABBV
GREZF yields 3.18% · ABBV yields 3.06%● Live data
📍 GREZF pulled ahead of the other in Year 4
Combined, GREZF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GREZF + ABBV for your $10,000?
GREE, Inc., a technology company, engages in the online media business in Japan and internationally. It operates through Internet and Entertainment, and Investment and Incubation segments. The company provides GREE, a social networking services (SNS) platform, and social games and diverse content closely linked with SNS, offering a variety of entertainment related elements centered on user-to-user communication; and develops and operates app games for smartphones under the GREE, WFS, Pokelabo, and GREE Entertainment brands to app delivery platforms. It also operates REALITY, a metaverse virtual live streaming app; REALITY XR cloud, a cloud solution for virtual events that take place in any virtual space; and REALITY STUDIO, a virtual creative label that has produced a wide variety of talent, including KMNZ, VESPERBELL, and HACHI. In addition, the company operates aumo, a travel and lifestyle information services platform; LIMIA, an on-line magazine that features home and living lifestyle content; MINE, an on-line video magazine that features women's fashion, beauty, and lifestyle topics; and ARINE, an on-line magazine for young women with the latest content on topics. Further, it provides DX support for client business based on experiences and achievements; and produces, develops, and directs anime and manga IP content. Additionally, the company invests in startup companies operating mainly in the Internet and IT fields through venture capital funds or corporate venture capital. GREE, Inc. was founded in 2004 and is headquartered in Tokyo, Japan.
Full GREZF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.